NVS News and Press, Novartis AG From 04/23/24

2024-04-23 11:15:11 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q1 2024 Earnings Call Apr 23, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q1 2024 Earnings Call Transcript

2024-04-23 10:00:00 ET Summary Novartis reported strong first quarter results with an EPS beat and revenue beat. The company's core growth products, including Entresto, Cosentyx, Kesimpta, Kisqali and Leqvio, drove the strong first-quarter performance. Novartis increased its f...

Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...

2024-04-23 05:15:48 ET More on related stocks: Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Nucor: A Solid Start To 2024 Novartis beats top-line and bottom-line...

2024-04-23 01:27:04 ET More on Novartis Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Novartis: Higher Guidance, Now A Buy FDA requires labeling changes to CAR-T...

2024-04-22 11:42:42 ET More on Novartis Novartis Looks To Get Back On Track With Q1 Earnings Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation Novartis: Higher Guidance, Now A Buy FDA requires labeling changes to CAR-T...

2024-04-19 14:48:33 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among ...

2024-04-19 11:02:48 ET Summary Novartis' Q1 outlook appears stable, with expectations of a rebound from a previous quarterly miss, projecting $11.57 billion in revenue. Key drugs like Fabhalta and Cosentyx may drive short-term growth, counteracting potential losses from generic co...

2024-04-19 07:03:48 ET Summary Since my last article, the company's share price has fallen about 10% despite its quarterly revenue growth and achieving significant success in developing experimental drugs. In addition to growing sales of next-generation drugs such as Ngenla, Bosul...

2024-04-19 06:13:03 ET More on Bristol-Myers Squibb, Gilead, etc. Johnson & Johnson: Buy This Bargain Before It's Gone Bristol-Myers Squibb: Market Pessimism Won't Last Forever Johnson & Johnson (JNJ) Q1 2024 Earnings Call Transcript FDA approves Alvo...